Why is Concord Drugs falling/rising?

As of 15-Jul, Concord Drugs Ltd is experiencing a decline in its stock price, currently at Rs 64.60, reflecting a decrease of Rs 2.4 or 3.58%. The stock has underperformed its sector today by 4.83% and has fallen after six consecutive days of gains. It opened with a loss of 3.58% and touched an intraday low of Rs 64.60. Despite this decline, the stock has shown impressive performance over the past year, generating a return of 65.64%, and has significantly outperformed the benchmark indices over various periods, including a 110.42% return over the past month. The stock is also trading higher than its moving averages across multiple time frames, indicating a generally positive trend prior to today's drop.
In the broader market context, while Concord Drugs has outperformed the Sensex with a 1-week return of 16.40% compared to the index's decline of 1.36%, the current downturn may be attributed to profit declines of 13% despite the stock's strong performance. The stock's attractive valuation, with a return on capital employed (ROCE) of 5.3 and a favorable enterprise value to capital employed ratio, suggests it is trading at a discount compared to peers. However, the recent price movement indicates a correction after a period of strong gains, which may have led to profit-taking among investors.